Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TissueGene-C in degenerative arthritis
NCT02341378Phase 2Completed
- Sponsor
- Kolon Life Science Inc.
- Start
- Aug 2009
- Primary completion
- Jun 2010
- Modality
- Gene Editing, Gene Silencing, Cell Therapies
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of Invossa in osteoarthritis (OA) (2 arms), sponsored by Kolon Life Science Inc. Primary endpoint: International Knee Documentation Committee Subjective Knee Evaluation at 24 weeks. Started Aug 2009; status: completed.
02
Drugs
Invossa
03
Conditions
osteoarthritis (OA)
Beyond the preview
Go deeper on NCT02341378.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02341378.